Mark Baum, Harrow CEO
July 19, 2023 10:51 AM EDT
Financing

Har­row prices $60M of­fer­ing one day af­ter ac­quir­ing US, Cana­di­an rights to new dry eye treat­ment

Paul Schloesser

Associate Editor

Eye biotech Har­row Health is look­ing to raise $60 mil­lion af­ter buy­ing the rights to an eye prod­uct new­ly ap­proved by the FDA.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times